Spineway obtains 510(ok) clearance from the FDA for its VEOS spinal fixation system
Ecully, October 19, 2023- Spineway Group, a specialist in modern implants for the remedy of extreme spinal situations, is happy to announce the current 510(ok) clearance from the US Food and Drug Administration (FDA) for its VEOS Spinal Fixation System.
This clearance, which permits Spineway Group to market its VEOS system within the US, represents a big achievement for the Group and reinforces its strategic method to develop its enterprise within the US market. This recognition additionally demonstrates the Group’s dedication to supply modern options to surgeons and to place the well-being of sufferers first.
Presentation on the NASS Congress in Los Angeles
This modern medical gadget is offered on the North American Backbone Society (NASS) Congress in Los Angeles till 21 October 2023.
The VEOS Spinal Fixation System is an entire platform that provides an modern and versatile resolution tailor-made to surgeons’ wants. The VEOS platform is straightforward to make use of, absolutely modular and optimizes operational excellence in working room.
This new providing permits surgeons to carry out open, minimally invasive and percutaneous surgical procedure (MIS) for the remedy of a variety of spinal pathologies, from degenerative spine to advanced surgical procedure and deformities.
“We’re very pleased with this FDA clearance, which permits Spineway Group to take step one in rolling out its new portfolio within the USA. This approval demonstrates our skill to develop modern options for the remedy of spinal pathologies that completely meet the wants of surgeons and sufferers. » says Stéphane Le Roux, CEO of Spineway.
Subsequent occasions: 18 to twenty October 2023: Participation within the NASS Congress – Los Angeles (USA) 10 November 2023: Extraordinary Normal Assembly
SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES) Discover out all about Spineway at www.spineway.com
This press launch has been ready in each English and French. In case of discrepancies, the French model shall prevail.
Spineway designs, manufactures and markets modern implants and surgical devices for treating extreme problems of the spinal column. Spineway has a global community of over 50 unbiased distributors and 90% of its income comes from exports. Spineway, which is eligible for funding by FCPIs (French unit trusts specializing in innovation), has obtained the OSEO Excellence award since 2011 and has gained the Deloitte Quick 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Expertise award (2015). ISIN: FR001400BVK2 – ALSPW